ACUTE MYELOID LEUKEMIA WITH FLT3/ITD MUTATION
Clinical trials for ACUTE MYELOID LEUKEMIA WITH FLT3/ITD MUTATION explained in plain language.
Never miss a new study
Get alerted when new ACUTE MYELOID LEUKEMIA WITH FLT3/ITD MUTATION trials appear
Sign up with your email to follow new studies for ACUTE MYELOID LEUKEMIA WITH FLT3/ITD MUTATION, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New drug combo targets Hard-to-Cure leukemia in early trial
Disease control Recruiting nowThis early-phase study tests whether combining two targeted drugs, SNDX-5613 and gilteritinib, is safe and effective for adults with a specific type of acute myeloid leukemia (AML) that has returned or not responded to treatment. The leukemia must have a FLT3 gene mutation plus e…
Matched conditions: ACUTE MYELOID LEUKEMIA WITH FLT3/ITD MUTATION
Phase: PHASE1 • Sponsor: Uma Borate • Aim: Disease control
Last updated May 26, 2026 12:06 UTC
-
New combo therapy targets Hard-to-Treat leukemia
Disease control Recruiting nowThis early-stage study tests a combination of two drugs, Vyxeos and Gilteritinib, in people whose FLT3-mutated acute myeloid leukemia has returned or not responded to prior treatment. The goal is to find the safest dose and see how many patients achieve remission. Participants wh…
Matched conditions: ACUTE MYELOID LEUKEMIA WITH FLT3/ITD MUTATION
Phase: PHASE1 • Sponsor: H. Lee Moffitt Cancer Center and Research Institute • Aim: Disease control
Last updated May 20, 2026 11:54 UTC
-
Heart check for leukemia drug: healthy volunteers wanted
Knowledge-focused Recruiting nowThis study checks if a single dose of XY0206, a drug being developed for a type of leukemia, changes the heart's electrical activity (QTc interval) in healthy people. About 45 to 75 healthy adults aged 18-45 will take one dose of XY0206, a placebo, or a control drug, and have the…
Matched conditions: ACUTE MYELOID LEUKEMIA WITH FLT3/ITD MUTATION
Phase: PHASE1 • Sponsor: Shijiazhuang Yiling Pharmaceutical Co. Ltd • Aim: Knowledge-focused
Last updated May 26, 2026 12:07 UTC